SMMT Stock Analysis: Summit Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 12.230m USD | 12M Return: -13.2% | US86627T1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 84.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies, with its lead candidate ivonescimab-a bispecific antibody designed to block PD-1 while simultaneously inhibiting angiogenesis-currently advancing through Phase III trials for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is also evaluating ivonescimab in combination with chemotherapy across multiple oncology indications, including EGFR-mutated NSCLC and first-line metastatic CRC. Founded in 2003 and headquartered in Miami, Florida, Summit markets across the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. As a biotechnology firm operating in the health care sector, the companys value is largely tied to clinical trial outcomes and regulatory milestones, which are typical drivers of valuation in the pre-commercial biopharma space.
- Ivonescimab Phase III NSCLC data readouts drive valuation
- FDA approval timeline and regulatory designations for ivonescimab
- Competition from rival PD-1 VEGF bispecific antibodies intensifies
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA 34.76 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -429.3m > Net Income -856.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (778.2m) vs 12m ago 4.68% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.82 (Total Current Assets 720.6m - Total Current Liabilities 103.6m) / Total Assets 752.2m |
| B: -3.59 (Retained Earnings -2.70b / Total Assets 752.2m) |
| C: -1.81 (EBIT TTM -856.0m / Avg Total Assets 473.4m) |
| D: 5.16 (Book Value of Equity 630.0m / Total Liabilities 122.2m) |
| Altman-Z'' = -13.06 = D |
As of October 30, 2026, the stock is trading at USD 16.20 with a total of 4,394,950 shares traded. Over the past week, the price has changed by +4.18%, over one month by -1.16%, over three months by +26.56% and over the past year by -13.18%.
Current recommended Stop Loss: 15.10 (which is 6.8% or 1.2 ATR below the current price).
Summit Therapeutics has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy SMMT.
- StrongBuy: 10
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30 | 85.2% |
Market Cap GBP = 9.18b (12.2b USD * 0.75041 USD.GBP)
P/E Forward = 3.7216
P/S = 3891.3077
P/B = 18.3614
Revenue TTM = 0.0 GBP
EBIT TTM = -856.0m GBP
EBITDA TTM = -855.9m GBP
Long Term Debt = 16.8m GBP (estimated: total debt 20.4m - short term 3.55m)
Short Term Debt = 3.55m GBP (from shortTermDebt, last quarter)
Debt = 20.4m GBP (from shortLongTermDebtTotal, last quarter) (leases 20.4m already included)
Net Debt = -670.3m GBP (calculated: Debt 20.4m - CCE 690.7m)
Enterprise Value = 8.51b GBP (9.18b + Debt 20.4m - CCE 690.7m)
Interest Coverage Ratio = unknown (Ebit TTM -856.0m / Interest Expense TTM 0.0)
EV/FCF = -19.76x (Enterprise Value 8.51b / FCF TTM -430.6m)
FCF Yield = -5.06% (FCF TTM -430.6m / Enterprise Value 8.51b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 108k) / Revenue TTM)
Tobins Q-Ratio = 11.31 (Enterprise Value 8.51b / Total Assets 752.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 20.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -676.3m (EBIT -856.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.96 (Total Current Assets 720.6m / Total Current Liabilities 103.6m)
Debt / Equity = 0.03 (Debt 20.4m / totalStockholderEquity, last quarter 630.0m)
Debt / EBITDA = 0.78 (negative EBITDA) (Net Debt -670.3m / EBITDA -855.9m)
Debt / FCF = 1.56 (negative FCF - burning cash) (Net Debt -670.3m / FCF TTM -430.6m)
Total Stockholder Equity = 431.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -180.8% (out of range, set to none)
RoE = -198.5% (Net Income TTM -856.1m / Total Stockholder Equity 431.3m)
RoCE = -191.0% (out of range, set to none) (EBIT -856.0m / Capital Employed (Equity 431.3m + L.T.Debt 16.8m))
RoIC = -103.7% (out of range, set to none) (NOPAT -676.3m / Invested Capital 652.2m)
WACC = 8.46% (E(9.18b)/V(9.20b) * Re(8.48%) + D(20.4m)/V(9.20b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.78 | Cagr: 4.70%
[DCF] Fair Price = unknown (Cash Flow -430.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.24 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.21 | Chg30d=+3.43% | Revisions=-55% | Analysts=12
EPS current Year (2026-12-31): EPS=-0.84 | Chg30d=+2.26% | Revisions=-36% | GrowthEPS=+21.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.88 | Chg30d=+1.26% | Revisions=-36% | GrowthEPS=-4.5% | GrowthRev=+1328.2%
[Analyst] Revisions Ratio: -52% (up=5, down=19)